ECSP22051163A - M?todos de tratamiento de hipertensi?n de la arteria pulmonar - Google Patents

M?todos de tratamiento de hipertensi?n de la arteria pulmonar

Info

Publication number
ECSP22051163A
ECSP22051163A ECSENADI202251163A ECDI202251163A ECSP22051163A EC SP22051163 A ECSP22051163 A EC SP22051163A EC SENADI202251163 A ECSENADI202251163 A EC SENADI202251163A EC DI202251163 A ECDI202251163 A EC DI202251163A EC SP22051163 A ECSP22051163 A EC SP22051163A
Authority
EC
Ecuador
Prior art keywords
methods
treatment
pulmonary artery
artery hypertension
patient
Prior art date
Application number
ECSENADI202251163A
Other languages
English (en)
Inventor
Loic Perchenet
Alessandro Maresta
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=73726769&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP22051163(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of ECSP22051163A publication Critical patent/ECSP22051163A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La descripci?n se relaciona con m?todos para reducir el riesgo de progresi?n de la enfermedad en un paciente con hipertensi?n arterial pulmonar (HAP), que comprende administrar a un paciente que lo necesita una terapia de combinaci?n triple inicial de un antagonista del receptor de endotelina (ARE), un inhibidor de fosfodiesterasa tipo 5 (PDE-5) y un agonista del receptor de prostaciclina (agonista del receptor de IP).
ECSENADI202251163A 2019-11-29 2022-06-28 M?todos de tratamiento de hipertensi?n de la arteria pulmonar ECSP22051163A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962941910P 2019-11-29 2019-11-29
US202063023452P 2020-05-12 2020-05-12
US202063076149P 2020-09-09 2020-09-09

Publications (1)

Publication Number Publication Date
ECSP22051163A true ECSP22051163A (es) 2022-07-29

Family

ID=73726769

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202251163A ECSP22051163A (es) 2019-11-29 2022-06-28 M?todos de tratamiento de hipertensi?n de la arteria pulmonar

Country Status (18)

Country Link
US (1) US12485119B2 (es)
EP (1) EP4065119B1 (es)
JP (3) JP7721520B2 (es)
KR (1) KR20220106974A (es)
CN (1) CN114728002A (es)
AU (1) AU2020392424A1 (es)
BR (1) BR112022010311A2 (es)
CA (1) CA3158292A1 (es)
CR (1) CR20220305A (es)
EC (1) ECSP22051163A (es)
ES (1) ES2994089T3 (es)
IL (1) IL293271A (es)
JO (1) JOP20220127A1 (es)
MX (1) MX2022006403A (es)
PE (1) PE20221320A1 (es)
PH (1) PH12022551294A1 (es)
TW (1) TW202133851A (es)
WO (1) WO2021105331A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120187431A (zh) * 2022-11-07 2025-06-20 埃科特莱茵药品有限公司 用于治疗肺动脉高血压的马西替坦和他达拉非的组合

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002227984B8 (en) 2000-12-18 2007-01-04 Actelion Pharmaceuticals Ltd. Novel sulfamides and their use as endothelin receptor antagonists
TWI316055B (es) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
US20050101608A1 (en) 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
PL1928409T3 (pl) 2005-09-12 2013-02-28 Actelion Pharmaceuticals Ltd Trwała kompozycja farmaceutyczna zawierająca pirymidynosulfamid
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
HRP20171917T1 (hr) 2008-08-13 2018-02-09 Actelion Pharmaceuticals Ltd. Terapeutski pripravci koji sadrže macitentan
KR102705198B1 (ko) 2009-06-26 2024-09-11 니뽄 신야쿠 가부시키가이샤 결정
WO2011024874A1 (ja) 2009-08-26 2011-03-03 日本新薬株式会社 塩基付加塩
JP5806320B2 (ja) 2010-10-15 2015-11-10 ギリアード サイエンシーズ， インコーポレイテッド 肺高血圧症を処置するための組成物および方法
WO2015163098A1 (ja) * 2014-04-22 2015-10-29 国立大学法人東北大学 肺高血圧症の検査方法
KR102569428B1 (ko) 2015-01-13 2023-08-21 비버스 인크. 폐 고혈압을 위한 병용 요법
BR112019008622A2 (pt) 2016-10-27 2019-07-09 Pulmokine Inc método para tratar uma condição
LT3897646T (lt) * 2018-12-21 2024-07-10 Actelion Pharmaceuticals Ltd Macitentanas plaučių arterinei hipertenzijai gydyti

Also Published As

Publication number Publication date
JP7721520B2 (ja) 2025-08-12
TW202133851A (zh) 2021-09-16
CR20220305A (es) 2022-07-28
US20230032813A1 (en) 2023-02-02
US12485119B2 (en) 2025-12-02
PE20221320A1 (es) 2022-09-08
KR20220106974A (ko) 2022-08-01
CN114728002A (zh) 2022-07-08
JP2024153734A (ja) 2024-10-29
JOP20220127A1 (ar) 2023-01-30
JP2025172745A (ja) 2025-11-26
CA3158292A1 (en) 2021-06-03
EP4065119B1 (en) 2024-09-04
AU2020392424A1 (en) 2022-06-02
IL293271A (en) 2022-07-01
JP7620758B2 (ja) 2025-01-23
JP2023504115A (ja) 2023-02-01
PH12022551294A1 (en) 2023-11-20
EP4065119A1 (en) 2022-10-05
MX2022006403A (es) 2022-08-25
BR112022010311A2 (pt) 2022-08-16
ES2994089T3 (en) 2025-01-17
WO2021105331A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
BR112014025460A8 (pt) endopróteses de cano duplo e desramificada em combinação e métodos para utilização
AR048588A1 (es) Uso de inhibidores de la fosfodiesterasa de tipo iii (pde iii) para la reduccion del tamano del corazon en mamiferos que padecen insuficiencia cardiaca
CL2020002774A1 (es) Tratamiento combinado de fibrosis y/o angiogénesis ocular
MX2018005715A (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash.
CO2021015793A2 (es) Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33
NI201700024A (es) Tratamientos médicos a base de anamorelina
CO2022005889A2 (es) Derivados terapéuticos de interleucina-22
CL2021003034A1 (es) Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton
PE20211199A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
ECSP22051163A (es) M?todos de tratamiento de hipertensi?n de la arteria pulmonar
PE20170469A1 (es) Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontano que utilizan composiciones de udenafilo
CL2025000581A1 (es) Estructuras derivadas de tn3 específicas de cd40l; tratamiento, prevención del síndrome de sjögren
CY1126058T1 (el) Αγωγη μιτοχονδριακων παθησεων
AR081925A1 (es) Uso de ranolazina para el tratamiento de la hipertension pulmonar
PE20210644A1 (es) METODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA
BR112018068960A2 (pt) formulações de enalapril
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina
CY1123322T1 (el) Φαρμακευτικη συνθεση περιλαμβανουσα μπισοπρολολη και περινδροπριλη
EP4456897A4 (en) ORAL FORMULATIONS OF LEVOSIMENDAN FOR THE TREATMENT OF PULMONARY HYPERTENSION WITH HEART FAILURE AND PRESERVED EJECTION FRACTION
PE20221314A1 (es) Formas de dosificacion y metodos para bupropion enantiomericamente enriquecido o puro
MX2025002392A (es) Formulaciones de dantroleno y metodos de uso de dichas formulaciones
CL2016000542A1 (es) Composición que comprende hidroxipropil quitosano junto con excipientes y/o adyuvantes farmacéuticamente aceptables; útil en el tratamiento de la onicomicosis.
EA202191612A1 (ru) Введение сулькардина для лечения острой фибрилляции предсердий
MX2021015561A (es) Composiciones farmaceuticas que contienen dapansutrilo.
AR120453A1 (es) Combinación de un inhibidor de btk y un inhibidor de mdm2 para el tratamiento del cáncer